Search clinical trials for: odanacatib

Total 19 results

Merck Sharp & Dohme LLC

Completed

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Hepatic Insufficiency
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Renal Insufficiency
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Odanacatib (0822-059)

Osteoporosis
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

Breast Cancer | Metastatic Bone Disease
Merck Sharp & Dohme LLC

Terminated

A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Osteoporosis | Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Osteoporosis Postmenopausal
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Osteoporosis

3

Subscribe